HROW 8-K 2026-11-09
HARROW, INC. (HROW) 8-K dated 2026-11-09 — accession 0001628280-26-072195.
HARROW, INC. (HROW) is a drug manufacturers - specialty & generic company listed on US.
HROW: Harrow Announces Third Quarter 2026 Financial Results
This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported HROW revenue for 2025-12-31 was $272.3M. Net income was -$5.1M. Revenue was up 36.4% from 2024-12-31 to 2025-12-31. HROW currently screens at market cap $1.28B.
Not investment advice. The HROW SEC hub lists recent forms. The stock page is the research view.
- Guidance
- full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40
Why it matters
- full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40
- The third quarter delivered the second-half acceleration we anticipated,…